The story of Viagra presents a interesting case for investors in the medicinal sector. While initially a blockbuster success, generating vast sums, the intellectual property lapse and the subsequent flood of off-brand competitors have significantly changed income. This presents questions about the future profitability of analogous therapeutic de… Read More